Ease: Empagliflozin Beneficial In Type 1 Diabetes Dka A Risk | Latest News RSS feed

Ease: Empagliflozin Beneficial In Type 1 Diabetes Dka A Risk - Latest News


EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk

BERLIN — The sodium-glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) improved glycemic control and weight in type 1 diabetes, but also increased ... read more

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Using actuarial methods*, and assuming that the demonstrated beneficial ... disease. JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones ... read more

Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetes

Empagliflozin ... their risk of DKA or other serious adverse events.” Based on the totality of the EASE data Boehringer Ingelheim has initiated regulatory discussions for empagliflozin as adjunct to i... read more

Looking for another news?


US FDA approves sNDA to add trial data in labels of three type 2 diabetes drugs within empagliflozin family

The data show that empagliflozin ... for the treatment of type 1 diabetes or diabetic ketoacidosis. Glyxambi has not been studied in patients with a history of pancreatitis, and it is unknown if using ... read more


Type 1 diabetes often misdiagnosed in adults

Despite having all of the symptoms common to type 1 diabetes, including rapid weight loss, her doctor initially said she had type 2 diabetes. After the prescribed medications didn't help ... condition ... read more

Lexicon Likely Looking At Even More Competition In Type 1 Diabetes

Lexicon could really use some good news, as the company ... s somewhat cryptic release regarding its EASE-2 and EASE-3 trials of Jardiance in Type 1 diabetes back in the summer created some hope that ... read more

Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetes

The EASE programme results were published online ... Canada. “Given the risk of DKA for people with type 1 diabetes, the 2.5 mg empagliflozin dose warrants consideration, as it balances glycaemic and ... read more

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

... is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. JARDIANCE is not for people with type 1 diabetes or for people with di... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

The number of adjudicated diabetic ketoacidosis events was comparable between empagliflozin 2.5 mg and placebo and higher than placebo in adults with type 1 diabetes on empagliflozin 10 mg and 25 mg. ... read more

It's Personal: EASD Focuses on Individualizing Diabetes Care

the Empagliflozin as Adjunctive to Insulin Therapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE) study. If successful, the results could lead to significant reductions in insulin requ... read more

Eli Lilly and Company (LLY) Management to Discuss EASD Presentations Conference Call (Transcript)

Good evening ... and kidney safety in adults with type 2 diabetes; as well the EASE program studied Jardiance as an adjunct to insulin in adults with type 1 diabetes. Over the next hour, we ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us